$13.49
0.31[2.35%]
At close: Apr 22
$13.49
0[0.00%]
PreMarket: 6:04PM EDT
Liquidia
(NASDAQ:LQDA)Latest News for Liquidia Stock (NASDAQ:LQDA)
Liquidia Stock (NASDAQ: LQDA)
Categories: All
Wednesday, April 10, 2024
Monday, April 01, 2024
- The Analyst Landscape: 5 Takes On LiquidiaBenzinga Insights - Apr 1, 2024, 2:00PM
- Needham Reiterates Buy on Liquidia, Maintains $28 Price TargetBenzinga Newsdesk - Apr 1, 2024, 10:27AM
- Liquidia Says Judge Andrews Has Set Aside Injunction Issued In August 2022 In Lawsuit Filed By United Therapeutics, Hence FDA Is No Longer Enjoined From Issuing Final Approval Of Liquidia New Drug Application For Yutrepia (Treprostinil) Inhalation PowderBenzinga Newsdesk - Apr 1, 2024, 6:09AM
Wednesday, March 27, 2024
Monday, March 18, 2024
Thursday, March 14, 2024
Wednesday, March 13, 2024
- Unveiling 6 Analyst Insights On LiquidiaBenzinga Insights - Mar 13, 2024, 5:00PM
- Needham Maintains Buy on Liquidia, Maintains $28 Price TargetBenzinga Newsdesk - Mar 13, 2024, 4:10PM
- Earnings Scheduled For March 13, 2024Benzinga Insights - Mar 13, 2024, 6:15AM
- Recap: iShares $ Corp Bond UCITS ETF Q4 EarningsBenzinga Insights - Mar 13, 2024, 6:15AM
- Liquidia FY GAAP EPS $(1.21) Misses $(1.02) Estimate, Sales $17.49M Miss $17.69M EstimateBenzinga Newsdesk - Mar 13, 2024, 6:06AM
Tuesday, March 12, 2024
Wednesday, February 21, 2024
- Needham Reiterates Buy on Liquidia, Maintains $28 Price TargetBenzinga Newsdesk - Feb 21, 2024, 1:18PM
- United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 EarningsVandana Singh - Feb 21, 2024, 1:17PM
- United Therapeutics Has Commenced Litigation Related To The FDA Inappropriately Denying United Therapeutics' Right To Obtain Stay Of Liquidia's Final Approval Until United Therapeutics' Pending Patent Infringement Claim Against Liquidia Can Be ResolvedBenzinga Newsdesk - Feb 21, 2024, 5:59AM
Monday, February 12, 2024
Thursday, January 25, 2024
- Liquidia Unusual Options Activity For January 25Benzinga Insights - Jan 25, 2024, 1:30PM
- The FDA Informed Liquidia That It Is Adding Pulmonary Hypertension Associated With Interstitial Lung Disease Indication As An Amendment To Yutrepia Application, Hence It Will Not Be Able To Meet The Prescription Drug User Fee Act Goal Date Of January 24Benzinga Newsdesk - Jan 25, 2024, 6:16AM
Tuesday, January 23, 2024
Monday, January 22, 2024
Wednesday, January 17, 2024
Friday, January 05, 2024
- Decoding 5 Analyst Evaluations For LiquidiaBenzinga Insights - Jan 5, 2024, 8:00AM
- Liquidia Provides Update On Clinical Pipeline Targeting PAH And PH-ILD, Says It Enrolled First PH-ILD Patient In The Open-label Ascent Study Of YutrepiaBenzinga Newsdesk - Jan 5, 2024, 6:59AM
- Needham Maintains Buy on Liquidia, Raises Price Target to $28Benzinga Newsdesk - Jan 5, 2024, 6:25AM
Friday, December 22, 2023
Thursday, December 21, 2023
- Ladenburg Thalmann Maintains Buy on Liquidia, Raises Price Target to $30Benzinga Newsdesk - Dec 21, 2023, 1:44PM
- B of A Securities Maintains Buy Rating for Liquidia: Here's What You Need To KnowBenzinga Insights - Dec 21, 2023, 12:00PM
- B of A Securities Maintains Buy on Liquidia, Raises Price Target to $15Benzinga Newsdesk - Dec 21, 2023, 11:24AM
- Wedbush Reiterates Underperform on Liquidia, Maintains $3 Price TargetBenzinga Newsdesk - Dec 21, 2023, 9:05AM
Wednesday, December 20, 2023
- Liquidia Says Federal Circuit Affirmed Earlier PTAB Decision To Invalidate All Claims Of United Therapeutics Patent No. 10,716,793 ('793 Patent)Benzinga Newsdesk - Dec 20, 2023, 4:58PM
- Why Is Pulmonary Hypertension-Focused Liquidia Stock Soaring Today?Vandana Singh - Dec 20, 2023, 2:04PM
- Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Dec 20, 2023, 1:16PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Dec 20, 2023, 12:31PM
- Liquidia shares are trading higher after the company won a patent case against United Therapeutics.Benzinga Newsdesk - Dec 20, 2023, 11:04AM
- Liquidia Wins Patent Case Against United Therapeutics; Federal Circuit Says "We Have Considered UTC's Remaining Arguments And Find Them Unpersuasive. For The Reasons Provided Above, We Affirm The Board's Unpatentability Determination"Benzinga Newsdesk - Dec 20, 2023, 10:17AM
- Toro Posts Upbeat Results, Joins Clear Channel Outdoor, Marathon Digital And Other Big Stocks Moving Higher On WednesdayAvi Kapoor - Dec 20, 2023, 10:10AM
- Liquidia Shares Halted On Circuit Breaker To The Upside, Stock Now Up 11.5%Benzinga Newsdesk - Dec 20, 2023, 9:46AM